ReviewLeukemia & lymphoma2014
Acute myeloid leukemia in the elderly: do we know who should be treated and how?
Review in Leukemia & lymphoma, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.Haematologica · 2018Trial
- Trial
- The Utility of Computed Tomography of the Chest at the Time of Induction Chemotherapy in Patients with Acute Leukemia.Cancers · 2026Article
- Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review.Cancers · 2023Review
- Acetylshikonin induces autophagy-dependent apoptosis through the key LKB1-AMPK and PI3K/Akt-regulated mTOR signalling pathways in HL-60 cells.Journal of cellular and molecular medicine · 2022Article
- Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry.PloS one · 2021Article
- Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults.PloS one · 2020Article
- The prognostic factors and efficacy of induction chemotherapy in elderly patients with acute myeloid leukemia.American journal of blood research · 2020Article
- Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index.Scientific reports · 2019Article
- Association of Mouse Double Minute 2 -309T>G Polymorphism with Acute Myeloid Leukemia in an Iranian Population: A Case- Control Study.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- [Treatment of 30 elderly patients with advanced myeloid neoplasm by allogeneic hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018Article
- Clinical decision making in cancer care: a review of current and future roles of patient age.BMC cancer · 2018Review
- miR-126 promotes the growth and proliferation of leukemia stem cells by targeting DNA methyltransferase 1.International journal of clinical and experimental pathology · 2018Article
- Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia.Current geriatrics reports · 2017Article
- Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells.Journal of hematology & oncology · 2016Article
- [Clinical studies of myeloablative dose conditioning prior to allogeneic hematopoietic stem cell transplantation for treatment of 12 patients over 55 years with high- risk malignant blood diseases].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Acute myeloid leukemia: advancing clinical trials and promising therapeutics.Expert review of hematology · 2016Review
- Efficacy of Compound Kushen Injection in Combination with Induction Chemotherapy for Treating Adult Patients Newly Diagnosed with Acute Leukemia.Evidence-based complementary and alternative medicine : eCAM · 2016Article
- Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.Biomaterials · 2015Article
- The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Abstract Acute myeloid leukemia (AML) in the elderly is associated with several distinctive biological and clinical features compared to younger patients. Despite the advances in supportive care and the introduction of less intensive chemotherapy regimens, the overall outcome for this population remains poor. More importantly, the decision making process for choosing the appropriate treatment for individual patients, based on their comorbidities and the biological features of their disease, continues to be challenging for treating physicians. Currently, a significant number of elderly patients with AML do not receive treatment above and beyond supportive care; several studies have suggested that patients who receive any therapy have a better outcome than patients who receive palliation alone. Furthermore, the development of novel, targeted and less intensive therapies is providing new options suitable for older patients with multiple comorbidities and with high risk disease features. In this review, we highlight the challenges that face treating physicians when encountering elderly patients with AML and describe some of the potential strategies under development for treating older patients with AML and the available data from recent clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.